Connection
Bradley Haverkos to Sezary Syndrome
This is a "connection" page, showing publications Bradley Haverkos has written about Sezary Syndrome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.147 |
|
|
|
-
Haverkos BM, Chang C, Ristuccia R, Chang Y, Friderici J, DeGutis IS, Rozati S. Treatment utilization and outcomes in patients with mycosis fungoides and Sézary syndrome receiving mogamulizumab in community and academic practice in the United States clinical practice. Leuk Lymphoma. 2026 Aug; 67(10):2035-2047.
Score: 0.955
-
Wang Z, Ma J, Zhang H, Ramakrishna R, Mintzlaff D, Mathes DW, Pomfret EA, Lucia MS, Gao D, Haverkos BM, Wang Z. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023 07; 13(7):1309-1319.
Score: 0.193